Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Arteris, Inc.'s SEC filings can feel like navigating a dense wiring diagram—hundreds of pages on deferred royalties, automotive safety certifications, and stock-based compensation. If you need the revenue backlog buried in a 10-K or want to spot Form 4 trades before the next design-win press release, the traditional EDGAR search simply takes too long.
Stock Titan solves this problem. Our AI-powered summaries translate complex semiconductor accounting into plain language, flagging key metrics such as licensing revenue mix, R&D capitalization trends, and customer concentration. Real-time alerts pull every Arteris quarterly earnings report 10-Q filing, 8-K material events explained in minutes, and Arteris insider trading Form 4 transactions as they post—so you never miss a disclosure.
Here’s what you can uncover instantly:
- Arteris annual report 10-K simplified—royalty schedules, risk factors, and segment performance distilled within seconds.
- Arteris Form 4 insider transactions real-time—track executive stock sales or option exercises alongside AI context on upcoming product milestones.
- Proxy statement executive compensation—see how design-win milestones affect equity awards without combing through tables.
- Arteris earnings report filing analysis—compare quarter-over-quarter gross margin shifts and R&D intensity.
Whether you’re monitoring executive stock transactions, assessing patent litigation exposure, or just trying to understand Arteris SEC filings explained simply, our platform surfaces the data professionals rely on—no jargon, no delays.
Arteris, Inc. (AIP) Form 4 filing: Chief Operating Officer Laurent R. Moll sold 294 shares of common stock on 1 Jul 2025 through a pre-arranged Rule 10b5-1 trading plan adopted 12 Mar 2025. The weighted-average sale price was $9.0869 per share, with transactions executed between $8.81 and $9.32. After the sale, Moll directly owns 483,465 shares of Arteris common stock. No derivative security activity was reported.
The transaction represents less than 0.1 % of Moll’s reported holdings and does not appear material to the company’s capital structure.
Arteris, Inc. (AIP) – Form 4 Insider Transaction
Director S. Atiq Raza, acting through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, sold 19,809 shares of Arteris common stock on 27 June 2025 under a pre-arranged Rule 10b5-1 trading plan adopted on 6 June 2024. The weighted-average sale price was $10.02 per share (individual trade prices ranged from $10.00 to $10.10).
Following the transaction, the trust continues to hold 683,798 shares, leaving Mr. Raza with a substantial ownership position. The filing states that the trade was reported on 1 July 2025 and was executed indirectly through the trust.
- Form type: SEC Form 4
- Insider role: Director
- Nature of trade: Open-market sale (code “S”)
- Approximate transaction value: $199,000
The relatively small percentage of shares sold (≈2.8 % of the insider’s reported holdings) and the existence of a 10b5-1 plan mitigate potential negative signalling, yet investors often monitor insider sales for sentiment clues.
Arteris, Inc. (symbol AIP) has filed a Form 144 indicating the planned disposition of 50,000 common shares through Morgan Stanley Smith Barney on or about 27 June 2025. At the most recent market price implied in the filing, the transaction is valued at approximately $479,000, representing roughly 0.12 % of the company’s 41,977,728 shares outstanding.
The person on whose behalf the sale will be made is listed as K. Charles Janac. Rule 144 requires disclosure of aggregate sales by the same holder; accordingly, the filing also details prior 10b5-1-related sales over the last three months totaling 19,603 shares for gross proceeds of $137,144.51. When combined with the proposed sale, the holder will have sold 69,603 shares during the period.
Form 144 further confirms that the seller attests to possessing no material non-public adverse information and, if operating under a 10b5-1 plan, has disclosed the plan adoption date. No relationship to the issuer or additional remarks were provided in the filing.
While the absolute number of shares is modest in relation to the float, continued insider dispositions may be monitored by investors as a potential sentiment signal.
The Form 144 filing indicates that an unidentified insider of Arteris, Inc. (ticker AIP) intends to sell common shares under Rule 144.
- Shares to be sold: 31,202 common shares
- Estimated market value: $298,915.16
- Total shares outstanding: 41,977,728 (sale represents roughly 0.07% of the float)
- Approximate sale date: 06/27/2025
- Broker: Morgan Stanley Smith Barney LLC, New York
- Acquisition origin: Restricted Stock Units (RSUs) granted and vested on 10/05/2022
No other sales by this insider were reported during the past three months, and no additional remarks or 10b5-1 plan details were supplied. While the dollar amount is modest, the disclosure fulfils SEC requirements and signals a forthcoming insider disposition.
Arteris, Inc. (AIP) – Form 144 insider sale notice
Senior insider Nicholas Hawkins filed a Form 144 indicating an intent to sell 5,638 common shares of Arteris on 26-27 June 2025 through Morgan Stanley Smith Barney. Based on the stated price, the shares carry an aggregate market value of $54,012.04. With 41,977,728 shares outstanding, the proposed sale represents roughly 0.013 % of the company’s equity, a de-minimis portion of the float.
The shares were originally acquired on 19 December 2019 via the cash exercise of stock options. The filing states the sale will occur under a Rule 10b5-1 trading plan, signalling the trades were pre-arranged and not based on undisclosed information.
Recent insider activity: The same insider has executed several sales over the past three months, amounting to 37,772 shares for approximately $302,155 in gross proceeds. Transaction sizes ranged from 438 to 11,000 shares per trade.
While insider sales do not automatically imply negative prospects, some investors monitor the frequency of such transactions. The currently disclosed sale remains immaterial relative to Arteris’ share count and does not on its own alter the investment thesis.
FAQ
What is the current stock price of Arteris (AIP)?
What is the market cap of Arteris (AIP)?
